CALL US NOW :
+91 124 423 0204
@@ Please be patient!! Your registration is in progress.
Anticoagulants are class of drug used for prevention of blood clots. These substances are majorly available in leeches and blood-sucking insects. These drugs have found major application in treatment of thrombotic disorders and as supporting drug during dialysis. The drug is applied on test tubes, transfusion bags, and renal dialysis equipment for proper functioning. Though the drug class results in various side effects; anticoagulants play an important role in treatment of atrial fibrillation, coronary artery disease, deep vein thrombosis, ischemic stroke, myocardial infraction and pulmonary embolism.
Global anticoagulants market is broadly divided by type into six segments including Heparin, Warfarin, Noval Oral Anticoagulants, Vitamin K Antogonists, Direct Thrombosis Inhibitors, and others. The market is also segmented on the basis of route of administration into oral and injections. Various global pharmaceutical giants including Pfizer, Sanofi, GSK, and Baxter provide anticoagulants in their portfolio for prevention of blood clots.
Aging population and rising prevalence of coagulation disorders are the major factors which are expected to drive the anticoagulants market during future. However, unawareness about the disease especially in emerging and undeveloped economies of Asia, Latin America and Africa results in large number of undiagnosed cases of coagulation disorders, hence restraining the market.
Tentative Scope- Global Anticoagulants Market
3.1. By Revenue, 2010-2015
4.1. By Type
220.127.116.11. Low Molecular Weight
18.104.22.168. Ultra Low Molecular Weight
4.1.2. Noval Oral Anticoagulants (NOACs)
22.214.171.124. Dabigatran Etexilate
4.1.3. Vitamin K Antagonists (VKA)
4.1.4. Injectable Direct Inhibitors
4.2. By Route of Administration
126.96.36.199. Intravenous Route
188.8.131.52. Subcutaneous Route
4.3. By Regions
4.3.1. North America
4.3.3. Asia Pacific
4.3.4. Rest of the World
5.1. Market by Revenue, 2010 – 2015
5.2. Market Segmentation
5.2.1. By Type(Heparin, VKA, NOACs, and Injectable Direct Inhibitors)
5.2.2. By Countries (US and Canada)
5.3. Import and Export Scenario
6.1. Market by Revenue, 2010 – 2015
6.2. Market Segmentation
6.2.1. By Type(Heparin, VKA, NOACs, and Injectable Direct Inhibitors)
6.2.2. By Countries (France, Germany, Italy, Spain, UK, and Rest of the Europe)*
6.3. Import and Export Scenario
7.1. Market by Revenue, 2010 – 2015
7.2. Market Segmentation
7.2.1. By Type(Heparin, VKA, NOACs, and Injectable Direct Inhibitors)
7.2.2. By Countries (China, India, Japan, Australia, and Rest of Asia Pacific)*
7.3. Import and Export Scenario
13.5.Bristol Myers Squibb
13.6.Teva Pharmaceutical Industries
13.7.Baxter Healthcare Corp.
14.1.By Revenues, 2016- 2020
14.2.By Segments, 2016-2020
14.3.Pipeline Analysis of Anticoagulants
Make a start to an incredible career
© Copyright 2017, KEN RESEARCH All rights reserved.